What is Human Longevity?
Founded in 2013, Human Longevity, Inc. is at the forefront of longevity medicine, leveraging advanced precision medicine techniques to promote healthy aging. The company's core focus lies in developing and applying genomic and data-driven insights to understand and influence the aging process. HLI's commitment to scientific innovation positions it as a key player in the rapidly expanding biotech and healthcare sectors, aiming to transform how individuals approach their long-term health and well-being.
How much funding has Human Longevity raised?
Human Longevity has raised a total of $370.8M across 5 funding rounds:
Series A
$80M
Series B
$220M
Other Financing Round
$30M
Debt
$1M
Series B
$39.8M
Series A (2014): $80M with participation from Daniel Curran, Synthetic Genomics, Illumina, Celgene, and Draper Fisher Jurvetson (DFJ)
Series B (2016): $220M led by Illumina, Celgene, and GE Ventures
Other Financing Round (2019): $30M supported by Emerging Technology Partners
Debt (2020): $1M featuring PPP
Series B (2024): $39.8M backed by Panacea Ventures, Emerging Technology Partners, and TVM Capital Healthcare Partners
Key Investors in Human Longevity
Illumina
Illumina, Inc. is a global leader in sequencing and array-based solutions for genetic and genomic analysis, providing critical tools and technologies for research and diagnostics in the life sciences sector.
GE Ventures
GE Ventures, the venture capital arm of General Electric, invests in companies that align with GE's focus on industrial technology, healthcare, and energy, driving innovation across these critical sectors.
Panacea Ventures
Panacea Capital is a global healthcare venture fund dedicated to investing in and transforming lives through innovations in the biotech and life sciences sectors, with a focus on unmet medical needs.
What's next for Human Longevity?
With the recent enterprise-level investment, Human Longevity, Inc. is strategically positioned for significant expansion. The company plans to bolster its presence within the U.S. market while simultaneously pursuing international growth, with specific targets in the Kingdom of Saudi Arabia and Southeast Asia. This global expansion, coupled with ongoing research and development in precision medicine, indicates a strong trajectory for the company as it seeks to capitalize on the growing demand for longevity-focused healthcare solutions. The strategic backing will likely fuel further innovation and market penetration.
See full Human Longevity company page
